{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:54:37Z","timestamp":1791644077473,"version":"4.3.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Ixchelsis Ltd, UK"},{"name":"Ixchelsis Ltd"},{"name":"Ixchelsis Ltd"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Cligosiban is an orally administered oxytocin receptor antagonist being developed to treat premature ejaculation (PE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To determine the safety and efficacy of cligosiban capsules (dose range 400\u2013800 mg) to improve intravaginal ejaculation latency time (IELT) and patient-reported outcomes in men with severe lifelong PE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients recorded details of at least 4 sexual intercourse events during a 4-week run-in period, after which they underwent baseline assessments. Patients were eligible for the study if they rated their control of ejaculation as poor\/very poor and their stopwatch-assessed IELT was \u22641 minute in \u226575% of intercourse attempts. Eligible patients were randomized to an 8-week treatment period with double-blind cligosiban or placebo (to be taken 1 to 6 hours prior to sexual activity). The starting dose was 400 mg (not more than 1 dose per day) which could be increased to 800 mg after 2 and\/or 4 weeks of treatment. Assessments were conducted at 2, 4, and 8 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>Efficacy measures were comprised of IELT, self-rating of ejaculation control and ejaculation-related distress (recorded in an electronic diary after each intercourse attempt), premature ejaculation profile, and the Clinical Global Impression of Change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean ratio of fold change from baseline in IELT to the last 4 weeks of treatment (cligosiban\/placebo) was 1.9 compared to a baseline of 1.0 (P = .0079). The mean increase in IELT from baseline to the last 4 weeks of treatment was 61.0 seconds for cligosiban, which was significantly different from (and 3.6-fold greater than) the mean increase of 16.4 seconds for placebo (P = .0086). Statistically significant improvements in ejaculation control and ejaculation-related personal distress scores were also observed for cligosiban compared to little or no change with placebo. Cligosiban was generally well tolerated, with no serious or severe adverse events or other safety parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>This proof-of-concept study demonstrated the potential for cligosiban, an oxytocin antagonist, to successfully treat symptoms of severe lifelong PE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>This was a Phase II, randomized, double-blind, placebo-controlled study that was adequately powered to detect a clinically meaningful difference in change in IELT between cligosiban and placebo. Larger studies will be needed to confirm these findings, determine the optimal dose of cligosiban and assess efficacy in men with acquired PE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Cligosiban was well tolerated, and resulted in significant benefits in both objective and subjective measures of ejaculatory control in men with lifelong PE and therefore offers significant potential as an on-demand, orally administered agent for the treatment of PE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2019.05.016","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T23:12:00Z","timestamp":1564009920000},"page":"1178-1187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX)"],"prefix":"10.1093","volume":"16","author":[{"given":"Christopher","family":"McMahon","sequence":"first","affiliation":[{"name":"Australian Centre for Sexual Health , St. Leonards, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Althof","sequence":"additional","affiliation":[{"name":"Center for Marital and Sexual Health of South Florida , West Palm Beach, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Rosen","sequence":"additional","affiliation":[{"name":"New England Research Institutes , Watertown, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Giuliano","sequence":"additional","affiliation":[{"name":"AP-HP , Versailles, \u00a0 France"},{"name":"Neuro-Uro-Andrology , Versailles, \u00a0 France"},{"name":"Physical Medicine and Rehabilitation Department , Versailles, \u00a0 France"},{"name":"Raymond Poincar\u00e9 Hospital , Versailles, \u00a0 France"},{"name":"Garches, France; UMR1179 Inserm\u2013Versailles Saint Quentin en Yvelines University , Versailles, \u00a0 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Miner","sequence":"additional","affiliation":[{"name":"Departments of Family Medicine and Urology , Providence, RI , USA"},{"name":"Men\u2019s Health Center , Providence, RI , USA"},{"name":"Miriam Hospital , Providence, RI , USA"},{"name":"Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"Osterloh","sequence":"additional","affiliation":[{"name":"Ixchelsis Ltd , Sandwich, \u00a0 UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Muirhead","sequence":"additional","affiliation":[{"name":"Ixchelsis Ltd , Sandwich, \u00a0 UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Harty","sequence":"additional","affiliation":[{"name":"New England Research Institutes , Watertown, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"2023012309454354600_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1743-6109.2004.10109.x","article-title":"Disorders of orgasm and ejaculation in men","volume":"1","author":"McMahon","year":"2004","journal-title":"J Sex Med"},{"key":"2023012309454354600_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.111.004952","article-title":"Pharmacology for the treatment of premature ejaculation","volume":"64","author":"Giuliano","year":"2012","journal-title":"Pharmacol Rev"},{"key":"2023012309454354600_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0018-506X(85)90002-9","article-title":"Oxytocin improves male copulatory performance in rats","volume":"19","author":"Arletti","year":"1985","journal-title":"Horm Behav"},{"key":"2023012309454354600_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0091-3057(89)90433-4","article-title":"Apomorphine stimulation of male copulatory behavior is prevented by the oxytocin antagonist d(CH2)5 Tyr(Me)-Orn8-vasotocin in rats","volume":"33","author":"Argiolas","year":"1989","journal-title":"Pharmacol Biochem Behav"},{"key":"2023012309454354600_bib5","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/bjp.2008.176","article-title":"Brain oxytocin receptors mediate ejaculation elicited by 7-hydroxy-2-(di-N-propylamino) tetralin (7-OH-DPAT) in anaesthetized rats","volume":"154","author":"Clement","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2023012309454354600_bib6","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1111\/jsm.12272","article-title":"Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study","volume":"10","author":"Shinghal","year":"2013","journal-title":"J Sex Med"},{"key":"2023012309454354600_bib7","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/bph.12198","article-title":"Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action","volume":"169","author":"Clement","year":"2013","journal-title":"Br J Pharmacol"},{"key":"2023012309454354600_bib8","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.jsxm.2018.10.008","article-title":"Cligosiban, a novel brain-penetrant, selective oxytocin receptor antagonist, inhibits ejaculatory physiology in rodents","volume":"15","author":"Wayman","year":"2018","journal-title":"J Sex Med"},{"key":"2023012309454354600_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jsxm.2018.09.006","article-title":"Pharmacokinetics, safety and tolerability of single oral doses of a novel oxytocin receptor antagonist cligosiban in development for premature ejaculation: three randomized clinical trials in healthy subjects","volume":"15","author":"Osterloh","year":"2018","journal-title":"J Sex Med"},{"key":"2023012309454354600_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jsxm.2018.11.012","article-title":"Pharmacokinetics, safety, and tolerability of multiple doses of the novel oxytocin receptor antagonist cligosiban in development for premature ejaculation: two randomized clinical trials in healthy subjects","volume":"16","author":"Muirhead","year":"2019","journal-title":"J Sex Med"},{"key":"2023012309454354600_bib11","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jsm.12524","article-title":"An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation","volume":"11","author":"Serefoglu","year":"2014","journal-title":"J Sex Med"},{"key":"2023012309454354600_bib12","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"2023012309454354600_bib13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1464-410X.2008.08041.x","article-title":"The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice","volume":"103","author":"Patrick","year":"2009","journal-title":"BJU Int"},{"key":"2023012309454354600_bib14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"2023012309454354600_bib15","article-title":"Columbia-Suicide Severity Rating Scale (C-SSRS): since last visit","author":"Posner"},{"key":"2023012309454354600_bib16","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/j.1743-6109.2010.01793.x","article-title":"Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation","volume":"7","author":"Althof","year":"2010","journal-title":"J Sex Med"},{"key":"2023012309454354600_bib17","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1743-6109.2008.00837.x","article-title":"Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies. Part II. Study design, outcome measures, data analysis, and reporting","volume":"5","author":"McMahon","year":"2008","journal-title":"J Sex Med"},{"key":"2023012309454354600_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.21037\/tau.2016.03.28","article-title":"The design and methodology of premature ejaculation interventional studies","volume":"5","author":"McMahon","year":"2016","journal-title":"Transl Androl Urol"},{"key":"2023012309454354600_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2826.1994.tb00549.x","article-title":"Increased Fos expression in oxytocin neurons following masculine sexual behavior","volume":"6","author":"Witt","year":"1994","journal-title":"J Neuroendocrinol"},{"key":"2023012309454354600_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.yhbeh.2010.12.012","article-title":"Oxytocin in the medial preoptic area facilitates male sexual behavior in the rat","volume":"59","author":"Gil","year":"2011","journal-title":"Horm Behav"},{"key":"2023012309454354600_bib21","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/j.1460-9568.2009.06999.x","article-title":"Dopamine-oxytocin interactions in penile erection","volume":"30","author":"Baskerville","year":"2009","journal-title":"Eur J Neurosci"},{"key":"2023012309454354600_bib22","doi-asserted-by":"crossref","first-page":"e1141","DOI":"10.1016\/j.juro.2017.02.2648","article-title":"MP84-07 performance and correlation of efficacy endpoints in a clinical trial of premature ejaculation","volume":"197","author":"Rosen","year":"2017","journal-title":"J Urol"},{"key":"2023012309454354600_bib23","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2006.07.004","article-title":"The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking","volume":"51","author":"Porst","year":"2007","journal-title":"Eur Urol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519312251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519312251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/8\/1178\/48589101\/jsm_16_8_1178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/8\/1178\/48589101\/jsm_16_8_1178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T10:23:05Z","timestamp":1674469385000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/16\/8\/1178\/6980624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.05.016","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,8,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}